Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: fexofenadine Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions

NCT00835276
View directory record Official record
Conditions
Healthy
Interventions
Fexofenadine 180 mg tablets, ALLEGRA® 180 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2009 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 4 Interventional Results available

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout

NCT03994731
View directory record Official record
Conditions
Gout
Interventions
Pegloticase, methotrexate, placebo, folic acid, gout flare prophylaxis regimen, fexofenadine, acetaminophen, methylprednisolone
Biological · Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
60
States / cities
Birmingham, Alabama • Anchorage, Alaska • Flagstaff, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 2, 2026, 2:26 PM EDT
Terminated Phase 2 Interventional Results available

Fexofenadine Use in Gastroesophageal Reflux Symptoms

NCT03425097
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Fexofenadine, Placebo - Cap
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Do Furanocoumarins Mediate the Fexofenadine-grapefruit Juice Interaction?

NCT01526213
View directory record Official record
Conditions
Food-drug Interaction
Interventions
Fexofenadine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

NCT07118215
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KarXT, Midazolam, Fexofenadine, Digoxin
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 50 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 4 Interventional

Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine

NCT00636870
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Fexofenadine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects

NCT02157558
View directory record Official record
Conditions
Drug Interactions
Interventions
Fexofenadine, Telotristat etiprate
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2014 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 4 Interventional Results available

Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout

NCT03635957
View directory record Official record
Conditions
Gout
Interventions
Pegloticase, Methotrexate (MTX), Standard Gout Flare Prophylaxis, Infusion Reaction (IR) Prophylaxis, Folic Acid
Biological · Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Anchorage, Alaska • Glendale, Arizona • Mesa, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Topical Treatment of Under Eye Dark Circles and Swelling

NCT01172522
View directory record Official record
Conditions
Edema
Interventions
Fexofenadine, Placebo
Drug
Lead sponsor
The Connecticut Sinus Center, PC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Effect of Antihistamines on Ureteral Stent-Related Symptoms

NCT04726345
View directory record Official record
Conditions
Nephrolithiasis
Interventions
Fexofenadine Hcl 180Mg Tab, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 4 Interventional Results available

A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

NCT06019728
View directory record Official record
Conditions
Fabry's Disease
Interventions
AGALSIDASE BETA (GZ419828), Acetaminophen, Diphenhydramine, Dexamethasone, Montelukast, Loratadine, Cetirizine, Fexofenadine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Santa Monica, California • Atlanta, Georgia • Grand Rapids, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 4 Interventional

Comparative Study Evaluating the Effects of Fexofenadine HCI 180 mg With Orange Juice Versus Placebo With Orange Juice in a Skin Wheal and Flare Challenge Model.

NCT00547768
View directory record Official record
Conditions
Allergy
Interventions
Fexofenadine HCI
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel

NCT00637455
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
fexofenadine HCl
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 4 Interventional

Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen

NCT00638118
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Fexofenadine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
15 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge

NCT00562120
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Placebo, Allegra, Allegra-D, PF-03654746
Drug
Lead sponsor
Pfizer
Industry
Eligibility
19 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg

NCT00649376
View directory record Official record
Conditions
Healthy
Interventions
Fexofenadine Tablets 180 mg, Allegra® Tablets 180 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Results available

Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome

NCT04093531
View directory record Official record
Conditions
Primary Sjögren Syndrome
Interventions
Ustekinumab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 2, 2026, 2:26 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

: Vascular Function in Health and Disease

NCT02966665
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Interventions
Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4
Other · Drug
Lead sponsor
Russell Richardson
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Aerobic Exercise with Blood Flow Restriction on Post-exercise Hypotension in Young Adults: the Role of Histamine Receptors

NCT06629337
View directory record Official record
Conditions
Prehypertension (elevated Blood Pressure) or Hypertension
Interventions
H1 receptor blockade: 540 mg (Allegra), H2 receptor blockade: 40 mg (Pepcid AC)
Genetic
Lead sponsor
California Baptist University
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 4 Interventional

Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine

NCT00637585
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Fexofenadine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Sep 2, 2026, 2:26 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Mast Cell Treatment in Post-tick Bite Illness (PTBI)

NCT07526558
View directory record Official record
Conditions
Post-tick Bite Illness, Mast Cell Stabilizer
Interventions
Ketotifen, fexofenadine, Cromolyn Sodium
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease

NCT02360644
View directory record Official record
Conditions
Chronic Kidney Diseases, Deficiency, Vitamin D
Interventions
Cholecalciferol
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
2
States / cities
Aurora, Colorado • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 4 Interventional Results available

Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

NCT00502775
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
fluticasone furoate, fexofenadine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
42
States / cities
Little Rock, Arkansas • Albany, Georgia • Columbus, Georgia + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Excipient Effect on Drug Absorption in Humans

NCT04534153
View directory record Official record
Conditions
The Impact of Excipients on Drug Absorption
Interventions
Fexofenadine Hydrochloride without sodium lauryl sulfate, Fexofenadine Hydrochloride with sodium lauryl sulfate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 2, 2026, 2:26 PM EDT